Search Results

You are looking at 71 - 80 of 262 items for :

  • "expectancy" x
  • Refine by Access: All x
Clear All
Full access

Prostate Cancer, Version 1.2016

James L. Mohler, Andrew J. Armstrong, Robert R. Bahnson, Anthony Victor D'Amico, Brian J. Davis, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric M. Horwitz, Michael Hurwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Joshua J. Meeks, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, David Raben, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ted A. Skolarus, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Seth A. Strope, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass

alternative hypothesis is that prostate cancer is becoming biologically less aggressive, but evidence is lacking. Early detection can lead to overtreatment of prostate cancers that do not threaten life expectancy, which results in unnecessary side NCCN

Full access

Treating Elderly Patients With Muscle-Invasive Bladder Cancer

Elizabeth R. Kessler, Janet B. Kukreja, Christopher L. Geiger, and Stacy M. Fischer

assessment of cognition. Cognitive ability can predict whether a patient can engage in care planning and help understand noncancer life expectancy in the setting of multimorbidity. The CGA provides critical information to help ground the approach to treatment

Full access

NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021

Featured Updates to the NCCN Guidelines

Efrat Dotan, Louise C. Walter, Ilene S. Browner, Katherine Clifton, Harvey Jay Cohen, Martine Extermann, Cary Gross, Sumati Gupta, Genevieve Hollis, Joleen Hubbard, Reshma Jagsi, Nancy L. Keating, Elizabeth Kessler, Thuy Koll, Beatriz Korc-Grodzicki, June M. McKoy, Sumi Misra, Dominic Moon, Tracey O’Connor, Cynthia Owusu, Ashley Rosko, Marcia Russell, Mina Sedrak, Fareeha Siddiqui, Amy Stella, Derek L. Stirewalt, Ishwaria M. Subbiah, William P. Tew, Grant R. Williams, Liz Hollinger, Giby V. George, and Hema Sundar

population and increasing life expectancies suggest that cancer in older adults is becoming increasingly prevalent. One of the challenges in managing older patients with cancer is assessing whether the expected benefits of treatment outweigh the risks in a

Full access

Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time

Filipa Lynce and Claudine Isaacs

cancer–specific mortality (3% vs 0.4%; HR, 0.21; 95% CI, 0.06–0.8). 4 Markov modeling suggests that a healthy 30-year-old woman with the mutation would gain 0.2 to 1.8 years in life expectancy with RRSO and 0.6 to 2.1 years from risk

Full access

The Role of the Private Sector in Health Care Reform

Elizabeth Danielson

, including coverage when the individual is enrolled in hospice Hospice when the individual has an estimated life expectancy of 12 months or less (rather than the usual 6 months) Genetic testing, and biomarker and molecular testing, consistent with

Full access

Hematopoietic Stem Cell Transplantation for Older Patients With Myelodysplastic Syndromes

H. Joachim Deeg and Marcos de Lima

of this reduced-intensity conditioning (RIC), or nonmyeloablative, transplant approach have aggressively pursued HCT of ever-older patients with MDS, other investigators have more cautiously weighed the pros and cons, with a focus on life expectancy

Full access

Beyond Median Overall Survival: Estimating Trends for Multiple Survival Scenarios in Patients With Metastatic Esophagogastric Cancer

Marieke Pape, Steven C. Kuijper, Pauline A.J. Vissers, Laurens V. Beerepoot, Geert-Jan Creemers, Hanneke W.M. van Laarhoven, and Rob H.A. Verhoeven

life expectancy to patients, which is more helpful than solely providing the median survival. In esophageal adenocarcinoma, the proportion of patients receiving systemic therapy increased and survival for the best-case scenario improved, in contrast

Full access

Toward Precision Pancreatic Cancer Care

Robert Goldberg

pancreatic cancer, a condition with poor life expectancy and few effective treatment options, costs more than it is worth. From that perspective, the most cost-effective strategy for a payer would be not to find more pancreatic cancer cases, primarily if

Full access

Cost-Effectiveness Analysis of Abiraterone and Sipuleucel-T in Asymptomatic Metastatic Castration-Resistant Prostate Cancer

Cynthia L. Gong and Joel W. Hay

expectancy, the time horizon for this analysis was lifetime to capture the full impact of drug treatment on overall survival benefit and lifetime costs. The model was run until 99% of patients were in the death state for each treatment arm. Figure 1

Full access

Adolescents and Young Adults Living With an Uncertain or Poor Cancer Prognosis: The “New” Lost Tribe

Vivian W.G. Burgers, Winette T.A. van der Graaf, Daniël J. van der Meer, Martin G. McCabe, Anita W. Rijneveld, Martin J. van den Bent, and Olga Husson

for AYAs with advanced cancer rarely extended life beyond 1 year. In recent years, the life expectancy of some patients with cancers that are common among AYAs, such as melanoma and Hodgkin lymphoma, have improved significantly following the